16 Nov 2026 | 07:25
London pre-open: Stocks seen flat as investors eye Nvidia earnings, Anthropic IPO
(Sharecast News) - London stocks were set for a flat open on Monday following some heavy losses in Asia, as investors eyed the latest quarterly earnings from scandal-hit Nvidia this week, as well as Anthropic's IPO.
The FTSE 100 was called to open steady at 10,902.
Ipek Ozkardeskaya, senior analyst at Swissquote, said: "The week starts on a bearish note, with technology under pressure this Monday morning. The Korean Kospi index - the first chart I opened this morning - is down by almost 4%, while the Japanese Nikkei has just extended losses beyond 2% at the time of writing. The US dollar index is steadying after reaching its highest level since April 2025, as last week's US inflation data cemented expectations that the Fed will hike rates next month and started a conversation about whether it should deliver a jumbo rate hike.
"This week, investors will watch US retail sales and the FOMC minutes, along with Canadian and British inflation updates, while technology will remain in focus with two important events on the calendar: Nvidia is due to release its Q3 earnings on Tuesday, after the bell. Anthropic is expected to start trading on Nasdaq on Thursday under the ticker ANT, with IPO pricing expected on Wednesday."
On home shores, investors will be mulling the latest figures from property portal Rightmove, which showed that house asking prices fell more sharply than usual in November as persistently high mortgage rates continued to squeeze buyers' budgets.
The average asking price of a newly listed property dropped by 1.8%, or £6,745, to £364,270 this month, compared with the 10-year average November decline of 1.1%.
Prices were also 0.2% lower than a year earlier, leaving the market on course to end 2026 below last year's levels.
Rightmove said sellers were increasingly adjusting their expectations to attract affordability-stretched buyers, with mortgage costs remaining a significant constraint.
The average two-year fixed mortgage rate stood at 5.51%, down slightly from 5.55% in October but well above the 4.25% recorded before the war in Iran began. That increase has added more than £200 a month to the cost of a typical new mortgage since February.
Meanwhile, the average two-year tracker rate was lower at 4.72%, although borrowers face greater uncertainty over monthly repayments.
Rightmove property expert Colleen Babcock said: "While we'd expect new sellers to set lower asking prices at this time of year due to the seasonality of the market, the larger-than-usual November fall suggests many sellers are aware that they need to price temptingly in the high mortgage rate market."
Regional differences remained pronounced, with asking prices falling across southern England over the past year. The South West recorded the steepest annual decline of 1.1%, while Scotland posted the strongest growth at 3.8%.
Flats continued to underperform houses, with asking prices down 1.7% annually compared with a 0.1% increase for houses.
Despite weaker prices, Rightmove said underlying market activity remained relatively resilient. The number of homes available for sale was at a 12-year high, while new buyer demand and agreed sales were down 8% and 7% respectively year-on-year.
New property listings, meanwhile, were 3% higher than a year earlier, adding to competition among sellers.
In corporate news, building supplies group Grafton reported a 2% rise in group revenue in the four months to 31 October as its Iberian and Irish operations offset a poor performance in Great Britain reflecting ongoing weakness in construction activity and subdued demand across both the repair and maintenance and new housebuilding markets.
The company maintained full-year guidance for adjusted operating profit of £190m to £200m.
Drugmaker AstraZeneca said that its rare disease division Alexion had secured regulatory approvals for Klygefa (gefurulimab) in both the European Union and the United States for the treatment of adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive.
The approvals from the European Commission and the Food and Drug Administration mark an important milestone for the therapy, which AstraZeneca said was the first and only approved dual-binding nanobody C5 inhibitor in both markets.
Both approvals were supported by results from the pivotal PREVAIL Phase III trial, which met its primary endpoint by delivering a statistically significant improvement in Myasthenia Gravis activities of daily living scores compared with placebo.
Elsewhere, drinks bottler Coca-Cola HBC said the Johannesburg Stock Exchange has granted it approval for a fast-tracked secondary listing.
The listing follows the acquisition by the Swiss-based, London-listed firm of Coca-Cola Beverages Africa, which is due to complete at the end of this month. The secondary listing and start of trading on the JSE will take effect a few days before that, on 23 November.
Coca-Cola HBC announced just over a year ago that it had agreed to buy a 75% stake in its African counterpart in a $2.6bn deal. Once complete, it will create the world's second-largest Coca-Cola bottling partner by beverage volume.